BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tafalla M, Buijssen M, Geets R, Vonk Noordegraaf-Schouten M. A comprehensive review of the epidemiology and disease burden of Influenza B in 9 European countries. Hum Vaccin Immunother. 2016;12:993-1002. [PMID: 26890005 DOI: 10.1080/21645515.2015.1111494] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Vigil A, Estélles A, Kauvar LM, Johnson SK, Tripp RA, Wittekind M. Native Human Monoclonal Antibodies with Potent Cross-Lineage Neutralization of Influenza B Viruses. Antimicrob Agents Chemother 2018;62:e02269-17. [PMID: 29507069 DOI: 10.1128/AAC.02269-17] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
2 Obul M, Wang X, Zhao J, Li G, Aisa HA, Huang G. Structural modification on rupestonic acid leads to highly potent inhibitors against influenza virus. Mol Divers 2019;23:1-9. [DOI: 10.1007/s11030-018-9840-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
3 Belazi S, Olsen SJ, Brown C, Green HK, Mook P, Nguyen-Van-Tam J, Penttinen P, Lansbury L. Spotlight influenza: Laboratory-confirmed seasonal influenza in people with acute respiratory illness: a literature review and meta-analysis, WHO European Region, 2004 to 2017. Euro Surveill 2021;26. [PMID: 34596019 DOI: 10.2807/1560-7917.ES.2021.26.39.2000343] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ray R, Dos Santos G, Buck PO, Claeys C, Matias G, Innis BL, Bekkat-Berkani R. A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control. Hum Vaccin Immunother 2017;13:1640-52. [PMID: 28532276 DOI: 10.1080/21645515.2017.1313375] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 5.4] [Reference Citation Analysis]
5 Kiseleva I, Krutikova E, Stepanova E, Donina S, Pisareva M, Krivitskaya V, Rekstin A, Sparrow EG, Torelli G, Rudenko L. Cross-Protective Efficacy of Monovalent Live Influenza B Vaccines against Genetically Different Lineages of B/Victoria and B/Yamagata in Ferrets. Biomed Res Int 2018;2018:9695628. [PMID: 30246028 DOI: 10.1155/2018/9695628] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
6 Stepanova E, Krutikova E, Wong PF, Matyushenko V, Bazhenova E, Isakova-Sivak I, Rudenko L. Safety, Immunogenicity, and Protective Efficacy of a Chimeric A/B Live Attenuated Influenza Vaccine in a Mouse Model. Microorganisms 2021;9:259. [PMID: 33513862 DOI: 10.3390/microorganisms9020259] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Marathe BM, Mostafa HH, Vogel P, Pascua PNQ, Jones JC, Russell CJ, Webby RJ, Govorkova EA. A pharmacologically immunosuppressed mouse model for assessing influenza B virus pathogenicity and oseltamivir treatment. Antiviral Res 2017;148:20-31. [PMID: 29100887 DOI: 10.1016/j.antiviral.2017.10.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
8 Sánchez-de Prada L, Rojo-Rello S, Domínguez-Gil M, Tamayo-Gómez E, Ortiz de Lejarazu-Leonardo R, Eiros JM, Sanz-Muñoz I. Influenza B Lineages Have More in Common Than Meets the Eye. Trivalent Influenza Vaccines Trigger Heterotypic Antibodies Against Both Influenza B Viruses. Front Microbiol 2021;12:737216. [PMID: 34858361 DOI: 10.3389/fmicb.2021.737216] [Reference Citation Analysis]
9 Moore RE, Xu LL, Townsend SD. Prospecting Human Milk Oligosaccharides as a Defense Against Viral Infections. ACS Infect Dis 2021;7:254-63. [PMID: 33470804 DOI: 10.1021/acsinfecdis.0c00807] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 21.0] [Reference Citation Analysis]
10 Koutsakos M, Kent SJ. Influenza B viruses: underestimated and overlooked. Microbiol Aust 2021;42:110. [DOI: 10.1071/ma21033] [Reference Citation Analysis]
11 Southgate JA, Bull MJ, Brown CM, Watkins J, Corden S, Southgate B, Moore C, Connor TR. Influenza classification from short reads with VAPOR facilitates robust mapping pipelines and zoonotic strain detection for routine surveillance applications. Bioinformatics 2020;36:1681-8. [PMID: 31693070 DOI: 10.1093/bioinformatics/btz814] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
12 Darricarrère N, Qiu Y, Kanekiyo M, Creanga A, Gillespie RA, Moin SM, Saleh J, Sancho J, Chou TH, Zhou Y, Zhang R, Dai S, Moody A, Saunders KO, Crank MC, Mascola JR, Graham BS, Wei CJ, Nabel GJ. Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates. Sci Transl Med 2021;13:eabe5449. [PMID: 33658355 DOI: 10.1126/scitranslmed.abe5449] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
13 Zapf AJ, Hardick J, McBryde B, Sauer LM, Fenstermacher KZJ, Ricketts EP, Lin YC, Chen KF, Hsieh YH, Dugas A, Shaw-Saliba K, Pekosz A, Gaydos CA, Rothman RE; Emergency Department National Network Influenza Investigators. Impact of coinfection status and comorbidity on disease severity in adult emergency department patients with influenza B. Influenza Other Respir Viruses 2021. [PMID: 34533270 DOI: 10.1111/irv.12907] [Reference Citation Analysis]
14 Ermler ME, Kirkpatrick E, Sun W, Hai R, Amanat F, Chromikova V, Palese P, Krammer F. Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model. J Virol 2017;91:e00286-17. [PMID: 28356526 DOI: 10.1128/JVI.00286-17] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 9.6] [Reference Citation Analysis]
15 Ping J, Lopes TJ, Neumann G, Kawaoka Y. Development of high-yield influenza B virus vaccine viruses. Proc Natl Acad Sci U S A 2016;113:E8296-305. [PMID: 27930325 DOI: 10.1073/pnas.1616530113] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
16 He D, Chiu AP, Lin Q, Yu D. Spatio-temporal patterns of proportions of influenza B cases. Sci Rep 2017;7:40085. [PMID: 28067277 DOI: 10.1038/srep40085] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
17 Hensen L, Kedzierska K, Koutsakos M. Innate and adaptive immunity toward influenza B viruses. Future Microbiology 2020;15:1045-58. [DOI: 10.2217/fmb-2019-0340] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Muralidharan A, Gravel C, Harris G, Hashem AM, Zhang W, Safronetz D, Van Domselaar G, Krammer F, Sauve S, Rosu-Myles M, Wang L, Chen W, Li X. Universal antibody targeting the highly conserved fusion peptide provides cross-protection in mice. Hum Vaccin Immunother 2022;:2083428. [PMID: 35724343 DOI: 10.1080/21645515.2022.2083428] [Reference Citation Analysis]
19 Dai Z, Zhang L, Yu Q, Liu L, Yang M, Fan K. Early Administration of Oseltamivir Within 48 Hours After Onset of Flulike Symptoms Can Reduce the Risk of Influenza B Virus-Associated Pneumonia in Hospitalized Pediatric Patients with Influenza B Virus Infection. Pediatr Infect Dis J. 2020;39:e20-e22. [PMID: 31929434 DOI: 10.1097/inf.0000000000002528] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Bhat YR. Influenza B infections in children: A review. World J Clin Pediatr 2020;9:44-52. [PMID: 33442534 DOI: 10.5409/wjcp.v9.i3.44] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Caini S, Kusznierz G, Garate VV, Wangchuk S, Thapa B, de Paula Júnior FJ, Ferreira de Almeida WA, Njouom R, Fasce RA, Bustos P, Feng L, Peng Z, Araya JL, Bruno A, de Mora D, Barahona de Gámez MJ, Pebody R, Zambon M, Higueros R, Rivera R, Kosasih H, Castrucci MR, Bella A, Kadjo HA, Daouda C, Makusheva A, Bessonova O, Chaves SS, Emukule GO, Heraud JM, Razanajatovo NH, Barakat A, El Falaki F, Meijer A, Donker GA, Huang QS, Wood T, Balmaseda A, Palekar R, Arévalo BM, Rodrigues AP, Guiomar R, Lee VJM, Ang LW, Cohen C, Treurnicht F, Mironenko A, Holubka O, Bresee J, Brammer L, Le MTQ, Hoang PVM, El Guerche-Séblain C, Paget J; Global Influenza B Study team. The epidemiological signature of influenza B virus and its B/Victoria and B/Yamagata lineages in the 21st century. PLoS One 2019;14:e0222381. [PMID: 31513690 DOI: 10.1371/journal.pone.0222381] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
22 Borchering RK, Gunning CE, Gokhale DV, Weedop KB, Saeidpour A, Brett TS, Rohani P. Anomalous influenza seasonality in the United States and the emergence of novel influenza B viruses. Proc Natl Acad Sci U S A 2021;118:e2012327118. [PMID: 33495348 DOI: 10.1073/pnas.2012327118] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
23 López Trigo JA, López Mongil R, Mariano Lázaro A, Mato Chaín G, Moreno Villajos N, Ramos Cordero P. [Seasonal flu vaccination for older people: Evaluation of the quadrivalent vaccine. Positioning report]. Rev Esp Geriatr Gerontol 2018;53 Suppl 2:185-202. [PMID: 30107941 DOI: 10.1016/j.regg.2018.06.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Montomoli E, Torelli A, Manini I, Gianchecchi E. Immunogenicity and Safety of the New Inactivated Quadrivalent Influenza Vaccine Vaxigrip Tetra: Preliminary Results in Children ≥6 Months and Older Adults. Vaccines (Basel) 2018;6:E14. [PMID: 29518013 DOI: 10.3390/vaccines6010014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
25 Chen Y, Leng K, Lu Y, Wen L, Qi Y, Gao W, Chen H, Bai L, An X, Sun B, Wang P, Dong J. Epidemiological features and time-series analysis of influenza incidence in urban and rural areas of Shenyang, China, 2010-2018. Epidemiol Infect 2020;148:e29. [PMID: 32054544 DOI: 10.1017/S0950268820000151] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
26 Sun W, Kang DS, Zheng A, Liu STH, Broecker F, Simon V, Krammer F, Palese P. Antibody Responses toward the Major Antigenic Sites of Influenza B Virus Hemagglutinin in Mice, Ferrets, and Humans. J Virol 2019;93:e01673-18. [PMID: 30381487 DOI: 10.1128/JVI.01673-18] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
27 Li Y, Ye X, Zhou J, Zhai F, Chen J. The association between the seasonality of pediatric pandemic influenza virus outbreak and ambient meteorological factors in Shanghai. Environ Health 2020;19:71. [PMID: 32552876 DOI: 10.1186/s12940-020-00625-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
28 Muralidharan A, Gravel C, Duran A, Larocque L, Li C, Zetner A, Van Domselaar G, Wang L, Li X. Identification of immunodominant CD8 epitope in the stalk domain of influenza B viral hemagglutinin. Biochem Biophys Res Commun 2018;502:226-31. [PMID: 29792863 DOI: 10.1016/j.bbrc.2018.05.148] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
29 Vigil A, Frias-Staheli N, Carabeo T, Wittekind M. Airway Delivery of Anti-influenza Monoclonal Antibodies Results in Enhanced Antiviral Activities and Enables Broad-Coverage Combination Therapies. J Virol 2020;94:e00052-20. [PMID: 32847855 DOI: 10.1128/JVI.00052-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Orsi A, Colomba GME, Pojero F, Calamusa G, Alicino C, Trucchi C, Canepa P, Ansaldi F, Vitale F, Tramuto F. Trends of influenza B during the 2010-2016 seasons in 2 regions of north and south Italy: The impact of the vaccine mismatch on influenza immunisation strategy. Hum Vaccin Immunother 2018;14:523-31. [PMID: 28708953 DOI: 10.1080/21645515.2017.1342907] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
31 Panatto D, Signori A, Lai PL, Gasparini R, Amicizia D. Heterogeneous estimates of influenza virus types A and B in the elderly: Results of a meta-regression analysis. Influenza Other Respir Viruses 2018;12:533-43. [PMID: 29498477 DOI: 10.1111/irv.12550] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
32 Knuf M, Kunze A. Influenza: Epidemiologie und neue Impfkonzepte. Monatsschr Kinderheilkd 2016;164:1004-11. [DOI: 10.1007/s00112-016-0182-z] [Reference Citation Analysis]
33 Pando R, Sharabi S, Mandelboim M. Exceptional influenza morbidity in summer season of 2017 in Israel may predict the vaccine efficiency in the coming winter. Vaccine 2018;36:1326-9. [PMID: 29429813 DOI: 10.1016/j.vaccine.2018.01.085] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
34 de Boer PT, van Maanen BM, Damm O, Ultsch B, Dolk FCK, Crépey P, Pitman R, Wilschut JC, Postma MJ. A systematic review of the health economic consequences of quadrivalent influenza vaccination. Expert Rev Pharmacoecon Outcomes Res 2017;17:249-65. [PMID: 28613092 DOI: 10.1080/14737167.2017.1343145] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
35 Zaraket H, Hurt AC, Clinch B, Barr I, Lee N. Burden of influenza B virus infection and considerations for clinical management. Antiviral Res 2021;185:104970. [PMID: 33159999 DOI: 10.1016/j.antiviral.2020.104970] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Huang WJ, Cheng YH, Tan MJ, Liu J, Li XY, Zeng XX, Tang J, Wei HJ, Chen T, Yang L, Xie YR, Yang JY, Xiao N, Wang DY. Epidemiological and virological surveillance of influenza viruses in China during 2020-2021. Infect Dis Poverty 2022;11:74. [PMID: 35768826 DOI: 10.1186/s40249-022-01002-x] [Reference Citation Analysis]
37 Trucchi C, Alicino C, Orsi A, Paganino C, Barberis I, Grammatico F, Canepa P, Rappazzo E, Bruzzone B, Sticchi L, Ansaldi F. Fifteen years of epidemiologic, virologic and syndromic influenza surveillance: A focus on type B virus and the effects of vaccine mismatch in Liguria region, Italy. Hum Vaccin Immunother 2017;13:456-63. [PMID: 27924684 DOI: 10.1080/21645515.2017.1264779] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
38 Nielsen J, Vestergaard L, Richter L, Schmid D, Bustos N, Asikainen T, Trebbien R, Denissov G, Innos K, Virtanen M, Fouillet A, Lytras T, Gkolfinopoulou K, Heiden MAD, Grabenhenrich L, Uphoff H, Paldy A, Bobvos J, Domegan L, O'donnell J, Scortichini M, de Martino A, Mossong J, England K, Melillo J, van Asten L, de Lange MM, Tønnessen R, White R, da Silva S, Rodrigues A, Larrauri A, Mazagatos C, Farah A, Carnahan A, Junker C, Sinnathamby M, Pebody R, Andrews N, Reynolds A, Mcmenamin J, Brown C, Adlhoch C, Penttinen P, Mølbak K, Krause T. European all-cause excess and influenza-attributable mortality in the 2017/18 season: should the burden of influenza B be reconsidered? Clinical Microbiology and Infection 2019;25:1266-76. [DOI: 10.1016/j.cmi.2019.02.011] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 11.7] [Reference Citation Analysis]
39 Mosnier A, Launay O, Martinez L, Gavazzi G, Josset L, Crepey P, Hannoun C, Weil-Olivier C, Gaillat J. [Quadrivalent influenza vaccine: What is changed and what are the benefits?]. Presse Med 2018;47:842-53. [PMID: 30219205 DOI: 10.1016/j.lpm.2018.06.013] [Reference Citation Analysis]